T-cell receptor gene therapy for cancer: the progress to date and future objectives.
In the last decade research has begun into the use of T-cell receptor (TCR) gene therapy as a means to control and eradicate malignancies. There is now a large body of evidence to demonstrate that through the use of this technology one can redirect T-cell antigen specificity to produce both cytotoxic and helper T cells, which are functionally competent both in vitro and in vivo and show promising antitumour effects in humans. This review focuses on the means by which TCR gene transfer is achieved and the recent advances to modify the TCRs and vector delivery systems which aim to enhance the efficiency and safety of TCR gene transfer protocols.
Thomas
Sharyn
S
Hart
Daniel P
DP
Xue
Shao-An
SA
Cesco-Gaspere
Michela
M
Stauss
Hans J
HJ
D000818:Animals; D015316:Genetic Therapy / Q000379:methods* / Q000639:trends; D005822:Genetic Vectors / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000235:genetics / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*; D011237:Predictive Value of Tests; D011948:Receptors, Antigen, T-Cell / Q000008:administration & dosage / Q000235:genetics* / Q000627:therapeutic use*
D011948:Receptors, Antigen, T-Cell